124 related articles for article (PubMed ID: 37459799)
1. ING1 inhibits Twist1 expression to block EMT and is antagonized by the HDAC inhibitor vorinostat.
Yang Y; Ma B; Djamshidi M; Zhang Q; Sarkar A; Chanda A; Tran U; Soh J; Sandall C; Chen HM; MacDonald JA; Bonni S; Sensen CW; Zheng J; Riabowol K
Eur J Cell Biol; 2023 Sep; 102(3):151341. PubMed ID: 37459799
[TBL] [Abstract][Full Text] [Related]
2. A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer.
Sakamoto T; Kobayashi S; Yamada D; Nagano H; Tomokuni A; Tomimaru Y; Noda T; Gotoh K; Asaoka T; Wada H; Kawamoto K; Marubashi S; Eguchi H; Doki Y; Mori M
PLoS One; 2016; 11(1):e0145985. PubMed ID: 26726879
[TBL] [Abstract][Full Text] [Related]
3. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
McLeod AB; Stice JP; Wardell SE; Alley HM; Chang CY; McDonnell DP
Prostate; 2018 Mar; 78(4):266-277. PubMed ID: 29243324
[TBL] [Abstract][Full Text] [Related]
4. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells.
Vasilatos SN; Katz TA; Oesterreich S; Wan Y; Davidson NE; Huang Y
Carcinogenesis; 2013 Jun; 34(6):1196-207. PubMed ID: 23354309
[TBL] [Abstract][Full Text] [Related]
5. Thymoquinone inhibits cancer metastasis by downregulating TWIST1 expression to reduce epithelial to mesenchymal transition.
Khan MA; Tania M; Wei C; Mei Z; Fu S; Cheng J; Xu J; Fu J
Oncotarget; 2015 Aug; 6(23):19580-91. PubMed ID: 26023736
[TBL] [Abstract][Full Text] [Related]
6. Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression.
Xu Y; Qin L; Sun T; Wu H; He T; Yang Z; Mo Q; Liao L; Xu J
Oncogene; 2017 Feb; 36(8):1157-1166. PubMed ID: 27524420
[TBL] [Abstract][Full Text] [Related]
7. Sox5 induces epithelial to mesenchymal transition by transactivation of Twist1.
Pei XH; Lv XQ; Li HX
Biochem Biophys Res Commun; 2014 Mar; 446(1):322-7. PubMed ID: 24607904
[TBL] [Abstract][Full Text] [Related]
8. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
9. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
Chen J; Li N; Liu B; Ling J; Yang W; Pang X; Li T
Life Sci; 2020 May; 248():117469. PubMed ID: 32109485
[TBL] [Abstract][Full Text] [Related]
10. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.
Bruzzese F; Leone A; Rocco M; Carbone C; Piro G; Caraglia M; Di Gennaro E; Budillon A
J Cell Physiol; 2011 Sep; 226(9):2378-90. PubMed ID: 21660961
[TBL] [Abstract][Full Text] [Related]
11. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.
Rhodes LV; Tate CR; Segar HC; Burks HE; Phamduy TB; Hoang V; Elliott S; Gilliam D; Pounder FN; Anbalagan M; Chrisey DB; Rowan BG; Burow ME; Collins-Burow BM
Breast Cancer Res Treat; 2014 Jun; 145(3):593-604. PubMed ID: 24810497
[TBL] [Abstract][Full Text] [Related]
12. Tripartite motif containing 28 (TRIM28) promotes breast cancer metastasis by stabilizing TWIST1 protein.
Wei C; Cheng J; Zhou B; Zhu L; Khan MA; He T; Zhou S; He J; Lu X; Chen H; Zhang D; Zhao Y; Fu J
Sci Rep; 2016 Jul; 6():29822. PubMed ID: 27412325
[TBL] [Abstract][Full Text] [Related]
13. Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.
Gatla HR; Zou Y; Uddin MM; Singha B; Bu P; Vancura A; Vancurova I
J Biol Chem; 2017 Mar; 292(12):5043-5054. PubMed ID: 28167529
[TBL] [Abstract][Full Text] [Related]
14. Human Schlafen 5 regulates reversible epithelial and mesenchymal transitions in breast cancer by suppression of ZEB1 transcription.
Wan G; Zhu J; Gu X; Yang Y; Liu Y; Wang Z; Zhao Y; Wu H; Huang G; Lu C
Br J Cancer; 2020 Aug; 123(4):633-643. PubMed ID: 32488136
[TBL] [Abstract][Full Text] [Related]
15. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
[TBL] [Abstract][Full Text] [Related]
16. Breast tumor cell-specific knockout of
Xu Y; Lee DK; Feng Z; Xu Y; Bu W; Li Y; Liao L; Xu J
Proc Natl Acad Sci U S A; 2017 Oct; 114(43):11494-11499. PubMed ID: 29073077
[TBL] [Abstract][Full Text] [Related]
17. Deacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex.
Smith KT; Martin-Brown SA; Florens L; Washburn MP; Workman JL
Chem Biol; 2010 Jan; 17(1):65-74. PubMed ID: 20142042
[TBL] [Abstract][Full Text] [Related]
18. LSD1 coordinates with the SIN3A/HDAC complex and maintains sensitivity to chemotherapy in breast cancer.
Yang Y; Huang W; Qiu R; Liu R; Zeng Y; Gao J; Zheng Y; Hou Y; Wang S; Yu W; Leng S; Feng D; Wang Y
J Mol Cell Biol; 2018 Aug; 10(4):285-301. PubMed ID: 29741645
[TBL] [Abstract][Full Text] [Related]
19. HDAC is indispensable for IFN-γ-induced B7-H1 expression in gastric cancer.
Deng R; Zhang P; Liu W; Zeng X; Ma X; Shi L; Wang T; Yin Y; Chang W; Zhang P; Wang G; Tao K
Clin Epigenetics; 2018 Dec; 10(1):153. PubMed ID: 30537988
[TBL] [Abstract][Full Text] [Related]
20. Twist1 and Slug mediate H2AX-regulated epithelial-mesenchymal transition in breast cells.
Weyemi U; Redon CE; Sethi TK; Burrell AS; Jailwala P; Kasoji M; Abrams N; Merchant A; Bonner WM
Cell Cycle; 2016 Sep; 15(18):2398-404. PubMed ID: 27315462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
